Validated high-performance liquid chromatography method for the determination of the inhibitor of cancer cell invasion (E)-N-benzyl-6-[2-(3, 4-dihydroxy benzylidene)hydrazinyl]-N-methylpyridine-3-sulfonamide in rat plasma and its application to pharmacokinetic study.
In this study, a reliable method for the quantitation of (E)-N-benzyl-6-[2-(3, 4-dihydroxy benzylidene)hydrazinyl]-N-methylpyridine-3-sulfonamide (JW-55) in rat plasma was developed and validated using high-performance liquid chromatography. Plasma samples were deproteinized; sildenafil was used as an internal standard. Chromatographic separation was achieved using a reversed-phase C18column. The mobile phase, 0.02 m ammonium acetate buffer:acetonitrile (48:52, v/v), was run at a flow rate of 1.0 mL/min at room temperature, and the column eluent was monitored using an ultraviolet detector at 280 nm. The retention times of JW-55 and sildenafil were ~5.9 and 7.7 min, respectively. The detection limit of JW-55 in rat plasma was 0.03 μg/mL. Pharmacokinetic parameters of JW-55 were evaluated after intravenous and oral administration of JW-55 (10 mg/kg) in rats. After oral administration, the F value was approximately 73.7%.
Department of Medicinal Chemistry, Jungwon University, Korea.
Tae Kon
TK
Kim
Department of Medicinal Chemistry, Jungwon University, Korea.
Hyun Kyung
HK
Choi
D061605:Administration, Intravenous; D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D011725:Pyridines / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*; D051381:Rats; D013449:Sulfonamides / Q000008:administration & dosage / Q000097:blood* / Q000493:pharmacokinetics*
C000620475:(E)-N-benzyl-6-(2-(3, 4-dihydroxy benzylidene)hydrazinyl)-N-methylpyridine-3-sulfonamide; D000970:Antineoplastic Agents; D011725:Pyridines; D013449:Sulfonamides
HPLC; Rab27a; bioavailability; intracellular membrane trafficking; protein-protein blocker; rats